Efficacy of a New Technique -"IN-REC-SUR-E"- in Preterm Neonates With RDS
Respiratory Distress Syndrome, Hyaline Membrane Disease
About this trial
This is an interventional treatment trial for Respiratory Distress Syndrome
Eligibility Criteria
Inclusion Criteria:
- In-Born at 24+0-27+6 (and)
- Spontaneously breathing at birth but requiring respiratory support (CPAP or O2) at 5' of life (and)
- Parental consent has been obtained (and)
- Failing nCPAP during the first 24 hours of life
Exclusion Criteria:
- Severe birth asphyxia or a 5-minute Apgar score <3
- Endotracheal intubation in the delivery room for resuscitation or insufficient respiratory drive according to AAP guidelines16
- Prolonged PROM > 3 weeks
- Presence of major congenital malformations
- Hydrops fetalis
- Inherited disorders of metabolism
Sites / Locations
- Ospedale Salesi
- Ospedale Di Venere
- Ospedale Maggiore
- Fondazione Poliambulanza
- Ospedale di Bolzano
- Pineta Grande
- S. Sebastiano e S. Anna
- Azienda Ospedaliera di Cosenza
- AOU Policlinico Vittorio Emanuele- Presidio Ospedaliero Gaspare Rodolico
- Ospedale Nuovo Garibaldi-Nesima
- Ospedale Vito Fazzi
- Ospedale Barone Romeo
- Ospedale san Pietro Fatebenefratelli
- Ospedale San Bortolo
- SS Antonio e Biagio e Cesare Arrigo
- Azienda Ospedaliera Universitaria Ferrara
- Careggi
- Ospedali Riuniti
- Ospedale San Salvatore
- Carlo Poma
- Università degli studi di Messina A.O.U. Policlinico G. Martino
- Mangiagalli
- Ospedale Niguarda
- A.O.U. di Modena Policlinico
- S. Gerardo
- Ospedale Maggiore
- Arnas Civico di Palermo
- A.O. Bianchi-Melacrino-Morelli
- Arcispedale Santa Maria Nuova
- Fatebenefratelli-Isola Tiberina
- Policlinico Gemelli-Università Cattolica S. Cuore
- A.O. Treviso Ospedale Cà Foncello
- Belcolle
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
INRECSURE
INSURE
Infants in the INRECSURE arm will undergo the following approach: as soon as possible after the recruitment manoeuver (at CDP-Optimal) a dose of poractant alfa (Curosurf [Chiesi Farmaceutici, Parma, Italy]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. A temporary reduction of frequency may be necessary to increase the VT up to 2.5 ml/kg for improving the surfactant spreading.
Infants in the INSURE arm will undergo the following approach: after intubation, a dose of poractant alfa (Curosurf [Chiesi Farmaceutici, Parma, Italy]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. During surfactant administration, infants will be manually ventilated to facilitate surfactant distribution.